| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vestibulocochlear Nerve Diseases | D000160 | 1 associated lipids |
| Acromegaly | D000172 | 6 associated lipids |
| Actinobacillus Infections | D000189 | 4 associated lipids |
| Actinomycosis | D000196 | 2 associated lipids |
| Addison Disease | D000224 | 3 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Angina, Unstable | D000789 | 14 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Zhang D et al. | [Expression of OPG and RANKL at protein level in human periodontal ligament cells and the effect of 1alpha,25(OH)(2) vitamin D(3) on the secretion of OPG protein in vitro]. | 2004 | Beijing Da Xue Xue Bao | pmid:15605102 |
| Guillonneau C et al. | The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. | 2004 | J. Immunol. | pmid:14734743 |
| Sudhoff H et al. | [Expression of osteoclast stimulating and differentiating factors in a murine model of localized inflammatory bone resorption]. | 2004 | Laryngorhinootologie | pmid:14740300 |
| Findlay DM et al. | The proliferation and phenotypic expression of human osteoblasts on tantalum metal. | 2004 | Biomaterials | pmid:14741587 |
| Theoleyre S et al. | Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. | 2004 | Biochim. Biophys. Acta | pmid:14741739 |
| Redlich K et al. | Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. | 2004 | Am. J. Pathol. | pmid:14742260 |
| Mogi M et al. | Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. | 2004 | J. Dent. Res. | pmid:14742657 |
| Heim M et al. | The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. | 2004 | Endocrinology | pmid:14605006 |
| Crotti TN et al. | Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. | 2004 | Biomaterials | pmid:14607494 |
| Vegni FE et al. | Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. | 2004 | N. Engl. J. Med. | pmid:14711922 |
| Kubota A et al. | Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. | 2004 | J. Rheumatol. | pmid:14994384 |
| Kötter I and Stübiger N | Therapeutic implications for interferon-alpha in arthritis. | 2004 | J. Rheumatol. | pmid:14994421 |
| Juji T and Tanaka S | [Novel therapeutic approach to bone metabolic disorders using RANKL vaccination]. | 2004 | Nippon Rinsho | pmid:15035230 |
| Huang JC et al. | PTH differentially regulates expression of RANKL and OPG. | 2004 | J. Bone Miner. Res. | pmid:14969393 |
| He J et al. | Emdogain promotes osteoblast proliferation and differentiation and stimulates osteoprotegerin expression. | 2004 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:14970783 |
| Ohazama A et al. | Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis. | 2004 | J. Dent. Res. | pmid:14981127 |
| Lowe CE et al. | Cost-effective analysis of candidate genes using htSNPs: a staged approach. | 2004 | Genes Immun. | pmid:15029236 |
| Brown JM et al. | Opg, RANKl, and RANK in cancer metastasis: expression and regulation. | 2004 | Cancer Treat. Res. | pmid:15043192 |
| Tay JY et al. | Identification of RANKL in osteolytic lesions of the facial skeleton. | 2004 | J. Dent. Res. | pmid:15044512 |
| Doran PM et al. | Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. | 2004 | Exp. Hematol. | pmid:15050745 |
| Kostenuik PJ et al. | Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. | 2004 | Bone | pmid:15050896 |
| Baek KH et al. | Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15001618 |
| Brage M et al. | Osteoclastogenesis is decreased by cysteine proteinase inhibitors. | 2004 | Bone | pmid:15003789 |
| Fukunaga J et al. | Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. | 2004 | Bone | pmid:15003790 |
| Skoumal M et al. | Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. | 2004 | Ann. Rheum. Dis. | pmid:14722219 |
| Brändström H et al. | Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women. | 2004 | Calcif. Tissue Int. | pmid:14508625 |
| WÅ‚odarski KH et al. | Influence of osteoprotegerin (OPG) on experimentally induced ectopic bone. | 2004 | Folia Biol. (Krakow) | pmid:19058561 |
| Ueland T | Bone metabolism in relation to alterations in systemic growth hormone. | 2004 | Growth Horm. IGF Res. | pmid:15519248 |
| Kitaura H et al. | Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. | 2004 | J. Immunol. | pmid:15470024 |
| Notoya M et al. | Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15474477 |
| Yip KH et al. | Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. | 2004 | J. Bone Miner. Res. | pmid:15476591 |
| Saidenberg-Kermanac'h N et al. | Role for osteoprotegerin in rheumatoid inflammation. | 2004 | Joint Bone Spine | pmid:14769514 |
| Abu-Amer Y et al. | TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. | 2004 | J. Cell. Biochem. | pmid:15389885 |
| Tian QX and Huang GY | [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. | 2004 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | pmid:15379268 |
| Nitta K et al. | Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. | 2004 | Am. J. Kidney Dis. | pmid:15384019 |
| Wang L et al. | Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). | 2004 | J. Bone Miner. Res. | pmid:15355561 |
| Nyambo R et al. | Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. | 2004 | J. Bone Miner. Res. | pmid:15355567 |
| Roux S and Mariette X | The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. | 2004 | Leuk. Lymphoma | pmid:15359989 |
| Wittrant Y et al. | RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. | 2004 | Biochim. Biophys. Acta | pmid:15363860 |
| Wada N et al. | Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. | 2004 | Bone | pmid:15336598 |
| Amato G et al. | High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. | 2004 | Bone | pmid:15336617 |
| Ono Y et al. | Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. | 2004 | Biol. Pharm. Bull. | pmid:15340228 |
| Farach-Carson MC et al. | Integrating rapid responses to 1,25-dihydroxyvitamin D3 with transcriptional changes in osteoblasts: Ca2+ regulated pathways to the nucleus. | 2004 | Steroids | pmid:15288767 |
| Vanderborght A et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. | 2004 | J. Rheumatol. | pmid:15290725 |
| Soufi M et al. | Osteoprotegerin gene polymorphisms in men with coronary artery disease. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15292302 |
| Schoppet M et al. | Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15292354 |
| Sato K | [Osteoclast-activating factors (OAF)]. | 2004 | Nippon Rinsho | pmid:15658306 |
| Haynes DR | Bone lysis and inflammation. | 2004 | Inflamm. Res. | pmid:15693607 |
| Kiefer JA et al. | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. | 2004 | Clin. Exp. Metastasis | pmid:15672862 |
| Kostenuik PJ | Revisiting the seed and soil theory of bone metastasis: new tools, same answer. | 2004 | J Musculoskelet Neuronal Interact | pmid:15758267 |
| Xu D et al. | Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. | 2004 | Biochem. J. | pmid:15250821 |
| De Leenheer E et al. | Evidence of a role for RANKL in the development of myeloma bone disease. | 2004 | Curr Opin Pharmacol | pmid:15251126 |
| Jung K et al. | Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. | 2004 | Int. J. Cancer | pmid:15252851 |
| Varga F et al. | Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. | 2004 | Calcif. Tissue Int. | pmid:15255076 |
| Miyashita T et al. | Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. | 2004 | Clin. Exp. Immunol. | pmid:15270863 |
| Nociti FH et al. | Cementoblast gene expression is regulated by Porphyromonas gingivalis lipopolysaccharide partially via toll-like receptor-4/MD-2. | 2004 | J. Dent. Res. | pmid:15271967 |
| Hashimoto T et al. | [Biochemical markers in bone metastasis]. | 2004 | Gan To Kagaku Ryoho | pmid:15272580 |
| Oh KW et al. | The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. | 2004 | Clin. Endocrinol. (Oxf) | pmid:15272921 |
| Doi S et al. | Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. | 2004 | Ther Apher Dial | pmid:15274686 |
| Stilgren LS et al. | Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. | 2004 | Bone | pmid:15207766 |
| Tsangari H et al. | Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. | 2004 | Bone | pmid:15207775 |
| Garlet GP et al. | Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. | 2004 | J. Clin. Periodontol. | pmid:15257746 |
| Baumann B et al. | Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. | 2004 | Acta Orthop Scand | pmid:15260421 |
| Tomek S et al. | Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. | 2004 | Gynecol. Oncol. | pmid:15262127 |
| Giuliani N et al. | Update on the pathogenesis of osteolysis in multiple myeloma patients. | 2004 | Acta Biomed | pmid:15796087 |
| Essalihi R et al. | Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin? | 2004 | J. Cardiovasc. Pharmacol. | pmid:15838266 |
| Xiao HL et al. | Expression and identification of mutated osteoprotegerin in culture cells and larvae of silkworm. | 2004 | Acta Biochim. Biophys. Sin. (Shanghai) | pmid:15156274 |
| Kim HH et al. | Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge. | 2004 | Biochem. Pharmacol. | pmid:15081864 |
| Pulsatelli L et al. | Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. | 2004 | Biogerontology | pmid:15105586 |
| Hofbauer LC et al. | Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. | 2004 | Acta Neuropathol. | pmid:15106011 |
| Suzuki T et al. | Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL). | 2004 | J. Bone Miner. Metab. | pmid:15108059 |
| Gonzalez-Calvin JL et al. | Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis. | 2004 | Gastroenterology | pmid:15057779 |
| Cheng Q et al. | [Effect of osteoprotegerin gene polymorphism on bone mass in postmenopausal women]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15059506 |
| Jang HD et al. | PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit. | 2004 | J. Biol. Chem. | pmid:15140884 |
| Granet C et al. | Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. | 2004 | Arthritis Res. Ther. | pmid:15142264 |
| Bengtsson AK et al. | 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. | 2004 | Blood | pmid:15142882 |
| Golledge J et al. | Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. | 2004 | Stroke | pmid:15143295 |
| Seshasayee D et al. | A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. | 2004 | J. Biol. Chem. | pmid:15145935 |
| Collin-Osdoby P | Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. | 2004 | Circ. Res. | pmid:15564564 |
| Neville-Webbe HL et al. | Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. | 2004 | Breast Cancer Res. Treat. | pmid:15567943 |
| Su X et al. | [Effects of parathyroid hormone on osteoprotegerin expression and osteoprotegerin ligand and their related cytokines in human osteoblasts]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16137047 |
| Fang TY et al. | [Serum osteoprotegrin and serum bone gamma-carboxyglutamine acid-containing protein are correlated with bone mineral density in normal women]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15569454 |
| Chondrogianni N et al. | Cloning of differentially expressed genes in skin fibroblasts from centenarians. | 2004 | Biogerontology | pmid:15609104 |
| Martinetti A et al. | Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. | 2004 | Endocr. Relat. Cancer | pmid:15613451 |
| Whyte MP and Mumm S | Heritable disorders of the RANKL/OPG/RANK signaling pathway. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615493 |
| Hofbauer LC et al. | The OPG/RANKL/RANK system in metabolic bone diseases. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615494 |
| Ritchlin CT et al. | RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615495 |
| Clohisy DR and Mantyh PW | Bone cancer pain and the role of RANKL/OPG. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615497 |
| Wang FS et al. | Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. | 2004 | Endocrinology | pmid:14962990 |
| Harashima SI et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. | 2004 | Rheumatology (Oxford) | pmid:14963213 |
| Hofbauer LC et al. | Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. | 2004 | Clin. Endocrinol. (Oxf) | pmid:14725683 |
| Yoneda T et al. | Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. | 2004 | Endocrinology | pmid:14726437 |
| Wittrant Y et al. | Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. | 2004 | Exp. Cell Res. | pmid:14729467 |
| Hruska KA et al. | Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. | 2004 | Semin. Nephrol. | pmid:14730507 |
| Zwerina J et al. | Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. | 2004 | Arthritis Rheum. | pmid:14730626 |
| Mallat Z and Tedgui A | Unbalanced RANKL/RANK pathway in aortic valve sclerosis. | 2004 | J. Mol. Cell. Cardiol. | pmid:14734042 |
| Kaden JJ et al. | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. | 2004 | J. Mol. Cell. Cardiol. | pmid:14734048 |
| Itonaga I et al. | Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. | 2004 | Bone | pmid:14751563 |
| Pan B et al. | The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). | 2004 | J. Bone Miner. Res. | pmid:14753746 |
| Valverde P et al. | Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. | 2004 | J. Bone Miner. Res. | pmid:14753747 |